Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jefferies Financial
JEF
5
Amazon
AMZN
CN Stock MarketDetailed Quotes
600276 Jiangsu Hengrui Pharmaceuticals
- 49.97
- 0.000.00%
Not Open Apr 29 09:30 CST
318.76BMarket Cap46.57P/E (TTM)
0.00High0.00Low0lotVolume0.00Open49.97Pre Close0.00Turnover0.00%Turnover Ratio50.32P/E (Static)6.38BShares57.5352wk High6.78P/B318.76BFloat Cap37.0452wk Low54.97Limit Up6.38BShs Float96.71Historical High44.97Limit Down0.00%Amplitude-0.95Historical Low0.20Dividend TTM--Avg Price0lotAsk0.40%Div YieldTTM100Lot Size0lotBid
About Jiangsu Hengrui Pharmaceuticals Company
The company was founded in 1970 and listed on the Shanghai Stock Exchange in 2000. It is an innovative international pharmaceutical enterprise focusing on R&D, production and promotion of high-quality drugs. It focuses on research and development of new drugs in the fields of oncology, metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience. It is one of the leading pharmaceutical companies with the most innovative capabilities in China. The company's main business involves R&D, production and sales of pharmaceuticals. Main products: pyrrolidinib maleate tablets, carrilizumab for injection, reverulamide tablets, hetrapopa ethanolamine tablets, iodophorol injections, butorphinol tartrate injections, etc. Corporate honors: “Environmental Exemplary Enterprise” and “Leading Green Development Enterprise” in Jiangsu Province, won the Lianyungang Economic and Technological Development Zone Enterprise “Environmental Protection Quality Award” in 2023, won the honorary title of “First Batch of Sterile Drug Quality Assurance Enterprises” issued by the China Pharmaceutical Quality Management Association, and the honorary title of “Jiangsu Pharmaceutical Industry Excellent Quality Management Enterprise” issued by the Jiangsu Pharmaceutical Quality Management Association; the company's “Young Eagle QC Group” and “Yuanzhi QC Group” were rated as Jiangsu Pharmaceutical Industry Quality Management (QC) Excellent Exchange Group and Jiangsu “Green Development Leader” Company” etc.
Company Profile
Short Name-A恒瑞医药
Symbol-A600276
Company NameJIANGSU HENGRUI MEDICINE CO.LTD
Listing DateOct 18, 2000
Issue Price11.98
Shares Offered40.00M share(s)
FoundedApr 28, 1997
Listed ExchangeSH Stock Exchange
Legal Representativepiaoyang sun
General Managerji feng
Secretaryxiaohan liu
Accounting FirmErnst & Young Huaming Certified Public Accountants (Special General Partnership)
Securities Representativefei tian
Legal CounselGuo Hao Law Firm (Nanjing)
Employees8738
Phone021-61053323
Office AddressNo. 7 Kunlunshan Road, Lianyungang Economic and Technological Development Zone, Jiangsu
Zip Code222000
Registered AddressNo. 38 Huanghe Road, Lianyungang Economic and Technological Development Zone, Jiangsu
Fax021-61063801
Emailir@hengrui.com
Websitehttps://www.hengrui.com
Business License320700000006736
BusinessTablets (including antineoplastic agents), oral solutions, suspensions, sterile raw materials (antineoplastic agents), raw materials (including antineoplastic drugs), psychotropic drugs, softgels (including antineoplastic drugs), freeze-dried powder injections (including antineoplastic drugs, cephalosporins), inhaled powders, oral suspensions, oral emulsions, high-volume injections (containing multi-layer co-extruded infusion bags, containing anti-tumor drugs), small-volume injections (containing non-antitumor drugs) Sterilized), bioengineered products (polyethylene glycol recombinant human granulocyte stimulating factor injection), hard capsules (including antineoplastic agents), granules Manufacture of agents (antineoplastic drugs), powders, membranes, gels, and creams; pre-treatment and extraction of traditional Chinese medicines; R&D, manufacture and sale of medical devices; sales of general chemical products; self-employment and agency of import and export business of various commodities and technologies, with the exception of goods and technologies operated by companies restricted by the state or prohibited from being imported and exported.
Company Executives
- Name
- Position
- Salary
- piaoyang sun
- Chairman, Directors, Chairman of the Strategy Committee, Nomination Committee Members
- 1.65M
- hongbin dai
- Vice Chairman, Directors, Strategy Committee Member, Member of the Remuneration and Assessment Committee
- 4.88M
- jieping sun
- Directors, Senior Vice President, Audit Committee Member
- 2.48M
- lianshan zhang
- Directors, Strategy Committee Member, Executive Vice President
- 3.90M
- ningjun jiang
- Directors, Authorized Representative, Executive Vice President, Strategy Committee Member
- 4.25M
- congzhao guo
- Directors, Strategy Committee Member
- --
- jien zhou
- Independent Directors
- --
- jinyun sun
- Independent Directors, Chairman of the Remuneration and Assessment Committee, Nomination Committee Members
- 100.00K
- qingsheng ceng
- Independent Directors, Chairman of the Audit Committee, Member of the Remuneration and Assessment Committee
- 100.00K
- jiahong dong
- Independent Directors, Chairman of the Nomination Committee, Strategy Committee Member, Audit Committee Member
- --
- xiaohan liu
- Board Secretary, Joint Company Secretary
- 850.70K
- fei tian
- Securities Affairs Representative
- --
- kaihong yuan
- Chairman of the Supervisory Board, Auditors
- 1.93M
- guoqiang xiong
- Auditors
- 344.30K
- ji feng
- General Manager (President)
- --
- jianjun liu
- Chief Financial Officer
- 2.28M
- yu xu
- Employee Supervisors
- 381.30K
- yingxian liang
- Authorized Representative, Joint Company Secretary
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs